Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety Open-label Study of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis Disease, an eXtension Study. The EYEGUARD-X Study

NCT02375685 is registered in ClinicalTrials.gov with Institut de Recherches Internationales Servier as lead sponsor.

NCT NCT02375685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02375685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety Open-label Study of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis Disease, an eXtension Study. The EYEGUARD-X Study
Lead sponsor
Institut de Recherches Internationales Servier
Phase
Phase 3
Overall status
Terminated
Start date
August 31, 2014
Completion date
November 30, 2015
Enrollment
71 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

chronic uveitis